MedTrace Logo

Autism Clinical Risk Factors Investigation With Microbiome and Metabolome Profiling

NCT05849233 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-05-08

No results posted yet for this study

Summary

The role of gut microbiome was recently raised in the pathogenesis of neurodevelopmental disorders including autism spectrum disorder (ASD). In view of these evidences, together with poor conductance of researches on gut microbiota in ASD patients in Egypt, in addition to the absence of definite medical test or biological marker for diagnosis of ASD, the present study is designed to study clinical risk factor of autism and the predominant gut microbiome in autistic children in an attempt to identify gut bacteria which are likely related to ASD and to correlate these bacteria and clinical variables with the severity of autism. Interestingly, the totality of the studies focusing on the fecal metabolome features in ASD has investigated the differences between subjects with and without this disorder, while ignoring potential correlations between microbiome, metabolome and ASD severity

Conditions

Interventions

OTHER

no intervention

no intervention

Sponsors & Collaborators

  • Ain Shams University

    collaborator OTHER

  • October University for Modern Sciences and Arts

    lead OTHER

Principal Investigators

  • sara Eladawy, PhD · MSa university

  • amira Abdeldaim, PhD · MSA university

Eligibility

Min Age
3 Years
Max Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05849233 on ClinicalTrials.gov